Under the agreement, CSL has got the rights for using a cell line for the cGMP production of an undisclosed antibody.
The licensed cell line was generated by utilizing SUREtechnology Platform of Selexis.
Selexis’ SURE Cell Line Development Technology Platform is based on Selexis Genetic Elements- novel DNA-based elements that control the organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins.
Selexis CEO Igor Fisch said they look forward to continuing to work with CSL.